Pharmaceutical Product Registration in Saudi Arabia - Overview

The Saudi Food and Drug Authority (SFDA) is the central authority overseeing pharmaceutical Regulatory affairs in Saudi Arabia and managing the SFDA drug registration and approval process. It regulates the full lifecycle of medicinal products, including manufacture, import, distribution, and post-marketing surveillance, aligned with the evolving global Regulatory standards.

All medicinal products must undergo pharmaceutical product registration at the SFDA before being marketed. The SFDA approval process is structured and increasingly digitized, requiring compliance with SFDA drug registration regulations and updated guidelines. Products are approved only if they meet stringent safety, efficacy, and quality standards, and manufacturing facilities must meet GMP compliance requirements in Saudi Arabia.

The SFDA drug registration timeline varies depending on the medicinal product type, review pathway, and dossier quality. Companies are encouraged to ensure strong Regulatory planning and accurate eCTD submission at SFDA to avoid delays.

Get help in Saudi Arabia’s drug registration and approval process.

Consult Freyr today!

Medicinal Product Classification in Saudi Arabia

In the Kingdom of Saudi Arabia (KSA), the Saudi Food and Drug Authority classifies medicinal products based on product type and their Regulatory pathway. Key categories include:

New Chemical Entities (NCEs) / innovative medicines
Generic medicines
Biological products (including biosimilars)

This classification framework determines the applicable SFDA drug registration pathway, data requirements, and review timelines.

Saudi Food and Drug Authority (SFDA) Drug Registration and Approval Process

Below is an overview of the SFDA drug registration and approval process:

A) Market Authorization

Phase 1

Step 1: Registration in the Drug Establishments National Registry (DENR)
Applicants must register in the DENR system to access SFDA electronic services and initiate the Saudi drug registration (SDR) system process.

Step 2: Marketing Authorization Application (MAA) Submission

Applications are submitted through the SDR system, aligned with SFDA drug registration regulations
Full eCTD submission in Saudi Arabia is required via the electronic portal (physical CD submissions are no longer standard practice).
Required documents include administrative forms, CPP (if applicable), and complete CTD modules.

Phase 2

Step 1: Validation
Applications undergo administrative and technical validation to ensure completeness and compliance with SFDA pharmaceutical Regulatory requirements, specifically for Module 1 (M1), which has to comply with the SFDA's latest approved M1 specification alongside eCTD full validation.

Step 2: Assessment, Testing, and Inspection

Scientific evaluation of quality, safety, and efficacy
Verification of GMP compliance to SFDA regulations through inspections or reliance mechanisms
Laboratory testing may be conducted where applicable

Step 3: Pricing
The SFDA reviews product pricing based on official pricing regulations and market considerations

Step 4: Product Licensing
Final approval is granted by the registration committee, completing the SFDA approval process

B) Reliance-Based Pathways

SFDA has strengthened reliance models to accelerate SFDA drug registration:

Verification Review – applicable when the medicinal product (New or Biologic) is approved by multiple reference agencies (e.g., United States Food and Drug Administration and European Medicines Agency)
Abridged Review – applicable when the medicinal product (New or Biologic) is approved by at least one recognized reference authority.

C) GMP Inspection Waivers

On-site GMP inspections may be waived if the manufacturing site is approved by recognized Regulatory authorities or GCC frameworks, supporting faster GMP compliance in Saudi Arabia verification

D) Mandatory Local Agent Requirement

Foreign manufacturers must appoint an authorized local agent in Saudi Arabia for Regulatory communication, pharmacovigilance coordination, and compliance with SFDA requirements

E) Import of Unregistered Products

SFDA allows controlled import of unregistered medicines in specific cases:

Critical or essential medicines
Products without available local alternatives

An import permit must be obtained for each shipment via the SFDA system

Product Maintenance & Compliance

Sr. No	Application	Validity
01	Validity for Registration Certificate	Five (05) years from the date of SFDA marketing authorization
02	Renewal of Registration Certificate	Renewal application should be submitted at least six (06) months before expiry
03	Post-approval Changes (Variations)	All variations must be submitted to the SFDA in accordance with variation guidelines and approved before implementation (where applicable). Verification Review and Abridged Review are applicable to Type II variations for New Clinical Entities (NCEs) and Biologics starting from January 2026 in order to support post-approval lifecycle alignments with reference agencies.